PK model [Regulatives / Guidelines]

posted by PharmCat  – Russia, 2020-09-10 18:12 (245 d 23:00 ago) – Posting: # 21915
Views: 2,091

Hi Helmut!

I can be wrong.

I suppose when we have modified release dosage form there are can be some changes in the PK model. We shold take in to accaunt that dissolution profile of form in GI can have own dynamic. For example: if absorbtion of dissoluted drug is high and dissolution is linear we can have something with "plato" profile. So resulting PK profile can be wery surprising.

Complete thread:

Activity
 Admin contact
21,460 posts in 4,486 threads, 1,514 registered users;
online 18 (0 registered, 18 guests [including 5 identified bots]).
Forum time: Friday 17:13 UTC (Europe/Vienna)

Art is “I”; science is “we”.    Claude Bernard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5